This broader applicability makes hemichannel therapies a promising alternative or adjunct to DUX4-specific treatments, particularly given the variability and unpredictability of DUX4 expression in FSHD muscle cells. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.